With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
DVLA lists every condition you need to declare or face £1,000 fine
It warns: "You need to tell DVLA about some medical conditions as they can affect your driving. You can be fined up to £1,000 ...
Pharm Exec7h
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...
Business Wire7h
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
manilatimes10h
FDA approves Roche's Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Susvimo provides continuous delivery of a customised formulation of ranibizumab via the Port Delivery Platform, while other currently approved treatments may require eye injections as often as once ...
ophthalmologyadvisor13h
Micronutrient Deficiencies Seen in More Than 45 Percent With Type 2 Diabetes
More than 45% of patients with type 2 diabetes (T2D) have micronutrient deficiencies, with the most prevalent deficiency ...
ophthalmologytimes16h
Study investigates neurological impact of diabetic vitreous hemorrhage
Diabetic vitreous hemorrhage is linked to neuropathologic changes in specific brain regions, as identified by voxel-based ...